Ceftolozane
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Ceftolozane: From Complicated Urinary Tract Infections to Ureaplasma urethritis
One-Sentence Summary
Ceftolozane is a novel cephalosporin antibiotic used internationally (in combination with tazobactam) for complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI), with FDA and EMA approval since 2014–2015. The TxGNN model predicts it may be effective for Ureaplasma urethritis, however this is supported by 0 clinical trials and 0 publications — representing model-level prediction only. Critically, the mechanistic rationale actively argues against this prediction: Ureaplasma organisms lack the peptidoglycan cell wall that beta-lactam antibiotics require to exert their effect.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not marketed in Canada; approved internationally for complicated UTI and complicated intra-abdominal infections (ceftolozane/tazobactam combination) |
| Predicted New Indication | Ureaplasma urethritis |
| TxGNN Prediction Score | 99.89% |
| Evidence Level | L5 |
| Canada Market Status | Not marketed |
| Number of DINs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on known pharmacology, ceftolozane is a fifth-generation cephalosporin that exerts its antibacterial effect by binding to penicillin-binding proteins (PBPs) on bacterial cell walls, thereby inhibiting peptidoglycan cross-linking and causing cell lysis. It is typically combined with the beta-lactamase inhibitor tazobactam (as Zerbaxa®) to combat drug-resistant Gram-negative organisms such as Pseudomonas aeruginosa.
However, the TxGNN prediction of Ureaplasma urethritis presents a fundamental mechanistic mismatch. Ureaplasma urealyticum belongs to the class Mollicutes, which entirely lacks a peptidoglycan cell wall — the very target through which beta-lactam antibiotics (including ceftolozane) work. Without PBP targets, ceftolozane has no established mechanism of action against Ureaplasma, and current standard-of-care guidelines recommend macrolides (azithromycin) or tetracyclines (doxycycline) for this pathogen.
This prediction most likely arises from indirect knowledge graph node connections (e.g., ceftolozane → urinary tract infections → urethritis → Ureaplasma urethritis) rather than a genuine mechanistic or clinical relationship. The high TxGNN score (99.89%) reflects graph topology proximity, not biological plausibility.
Clinical Trial Evidence
Currently no related clinical trials registered for ceftolozane and Ureaplasma urethritis.
Literature Evidence
Currently no related literature available for ceftolozane and Ureaplasma urethritis.
Canada Market Information
Ceftolozane is currently not approved or marketed in Canada. No Drug Identification Numbers (DINs) are on record.
Safety Considerations
Please refer to the package insert for safety information.
Appendix: Additional Predicted Indications (Ranks 2–10)
The following table summarizes the remaining TxGNN-predicted indications and their scientific viability, to provide a complete picture of the model’s output for this drug.
| Rank | Disease | Score | Evidence Level | Assessment |
|---|---|---|---|---|
| 1 | Ureaplasma urethritis | 99.89% | L5 | Biologically implausible — Ureaplasma lacks cell wall (no PBP target for beta-lactams) |
| 2 | Gonococcal urethritis | 99.89% | L5 | Theoretically possible but no MIC data or clinical trials; not in CDC/WHO STI guidelines |
| 3 | Uterine inflammatory disease | 99.88% | L5 | Incomplete coverage — PID requires anaerobic cover; ceftolozane alone is insufficient |
| 4 | Xanthogranulomatous pyelonephritis | 99.88% | L4 | Indirect support only — ceftolozane/tazobactam approved for cUTI; XGP usually requires surgery |
| 5 | Polyclonal hyperviscosity syndrome | 99.52% | L5 | Biologically implausible — immunoglobulin disorder unrelated to antibacterial mechanism |
| 6 | Hyperamylasemia | 99.52% | L5 | Biologically implausible — metabolic marker; beta-lactams may cause this as a side effect, not treat it |
| 7 | Urogenital tuberculosis | 99.50% | L5 | Biologically implausible — MTB expresses BlaC beta-lactamase; ceftolozane not active against MTB |
| 8 | Congenital analbuminemia | 99.44% | L5 | Biologically implausible — genetic albumin synthesis disorder; graph artifact via protein-binding nodes |
| 9 | Blood group incompatibility | 99.22% | L5 | Biologically implausible — ABO/Rh immune reaction; no antibacterial relevance |
| 10 | Premalignant hematological disease | 99.11% | L5 | Biologically implausible — clonal stem cell disorder; ceftolozane has no antiproliferative mechanism |
Note: Rank 4 (xanthogranulomatous pyelonephritis) is the only prediction with any indirect mechanistic support, given the established approval of ceftolozane/tazobactam for complicated UTI/acute pyelonephritis. However, XGP is a rare chronic condition typically requiring nephrectomy, and no XGP-specific trials exist. This could be considered a Research Question for case-report or retrospective study design.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked TxGNN prediction (Ureaplasma urethritis) is biologically implausible — ceftolozane’s mechanism of action requires a peptidoglycan cell wall target that Ureaplasma organisms do not possess. Across all 10 predicted indications, 9 are rated L5 (model prediction only) with no supporting evidence, and several carry mechanistic arguments actively opposing the prediction. The one indication with marginal support (xanthogranulomatous pyelonephritis, L4) is a rare surgical condition where antibiotics play only an adjunctive role.
To proceed, the following is needed:
- MOA data (DG002): Obtain complete mechanism of action from DrugBank API to enable proper mechanistic link analysis
- Canada regulatory data: Investigate Health Canada DPD for any ceftolozane/tazobactam (Zerbaxa®) submissions or compassionate-use programs
- Re-rank predictions: Consider filtering out predictions with explicit mechanistic counter-evidence before investing in further evidence collection
- Refocus on rank 4 (XGP) if pursuing UTI space: Conduct a targeted literature search for case reports of ceftolozane use in complex/recurrent pyelonephritis to assess if a retrospective case series is feasible
- Gonococcal urethritis (rank 2): If pursuing STI indications, commission in vitro MIC susceptibility testing for N. gonorrhoeae as a minimal pre-clinical data requirement before any clinical hypothesis generation
This report is generated for research reference purposes only and does not constitute medical advice. All drug repurposing candidates require clinical validation before any therapeutic application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.